CZChao Zhang

Chao Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chao Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of the combination of dexmedetomidine and azasetron on the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery

    by Jing Wang, Jing Chi, Hui Cao, XingGen Zhou, Ming Yao, XiaoPing Shen, ZhangZhen Zhong, ZiYi Shen, Jie Wang, Chao Zhang

  • Open Access

    Argon Alleviates Bone Cancer Pain by Mitigating Neuronal Ferroptosis via the TLR2-COX-2 Pathway

    by Peipei Kang, Gujun Cong, Xiaowen Meng, Yang Zhang, Haiyan Sun, Lei Wang, Chao Zhang, Junyi Ma, Tong Liu, Fuhai Ji

    Background: Bone cancer pain (BCP) related neuronal damage is associated with ferroptosis, a regulated cell death dependent on iron. The noble gas argon is known to have neuroprotective effects, reducing neuroinflammation and enhancing neuronal recovery. However, its potential role in alleviating BCP through the modulation of neuronal ferroptosis remains unexplored. Methods: Ferroptosis was induced by Erastin in SH-SY5Y human neuroblastoma cells. Plasmids were used to overexpress or knock down toll-like receptor (TLR) 2 and cyclooxygenase-2 (COX-2). The effects of argon treatment were evaluated in SH-SY5Y cells in which TLR2 and COX-2 expression was manipulated using viability assays, oxidative stress markers (reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH)), and ferroptosis-related proteins (acyl-CoA synthetase long-chain family member 4 (ACSL4), glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11)). In vivo, a murine BCP model was developed by injecting Lewis lung carcinoma cells into the femoral cavity. Pain behaviors were analyzed, and spinal cord ferroptosis features were evaluated using histology, immunofluorescence, and transmission electron microscopy (TEM). Results: In vitro experiments showed that argon treatment restored SH-SY5Y cell viability after Erastin exposure, suppressed ROS and MDA production, and boosted GSH levels. It also downregulated ACSL4 and upregulated GPX4 and SLC7A11. In vivo, argon improved pain behaviors, reduced tumor burden, preserved neuronal integrity, and mitigated ferroptosis-induced damage to the spinal cords of BCP model mice. Argon also significantly suppressed TLR2 and COX-2 expression, disrupting the ferroptosis and inflammation cascades. However, overexpression of TLR2 or COX-2 reversed these protective effects, confirming the pivotal role of the TLR2-COX-2 axis in neuronal ferroptosis and pain modulation. Conclusion: These findings demonstrate that argon effectively mitigates neuronal ferroptosis and alleviates BCP by downregulating the TLR2-COX-2 pathway, highlighting its therapeutic potential for conditions involving ferroptosis, such as cancer-related pain and neurodegenerative diseases.


  • Open Access

    Combination of dexmedetomidine and esketamine for postoperative nausea and vomiting in patients undergoing laparoscopic surgery: study protocol for a prospective, randomized, controlled trial

    by Ying Zhou, Ziyi Shen, Jinbiao Li, Hui Cao, Xinggen Zhou, Weicheng Jin, Ming Yao, Jing Chi, Jie Wang, Chao Zhang

    Laparoscopic surgery has gained widespread acceptance due to its advantages over traditional open procedures, including less postoperative pain and faster recovery. However, postoperative nausea and vomiting (PONV) remains a prevalent complication, affecting up to 80% of high-risk patients and significantly reducing patient satisfaction and recovery quality. Although opioids are frequently used for intraoperative analgesia, their side effects, particularly PONV, highlight the need for opioid-sparing strategies. Dexmedetomidine and esketamine are two agents with analgesic and anesthetic-sparing properties that have shown promise individually in reducing PONV and postoperative pain. However, evidence remains limited, and no study has systematically evaluated the combined use of dexmedetomidine and esketamine for PONV prevention in laparoscopic surgery. This trial aims to fill this knowledge gap by assessing the efficacy and safety of this novel combination strategy, potentially offering an improved anesthetic regimen for enhanced postoperative recovery. To address this gap, we propose a prospective, randomized, controlled trial (RCT) at a single center to evaluate the effects of dexmedetomidine and esketamine on PONV in laparoscopic surgery patients. Patients will be randomly assigned to either the combination therapy group or the control group in a 1:1 ratio. The combination therapy group (n = 70) will receive intravenous dexmedetomidine (0.5 μg/kg), esketamine (0.3 mg/kg), sufentanil (0.2 μg/kg) and propofol (1.5–2.0 mg/kg) for anesthesia induction, with sevoflurane (2–3%) used for maintenance during surgery. Conversely, the control group (n = 70) will receive sufentanil (0.5 μg/kg) and propofol (1.5–2.0 mg/kg) for anesthesia induction, followed by sevoflurane (2–3%) inhalation and continuous remifentanil infusion (0.1 μg/kg/min) for maintenance. The primary outcome is the incidence of PONV within 48 h postoperatively, assessed during three predefined intervals: 0–6 h, 6–24 h, and 24–48 h. Secondary outcomes include Apfel PONV risk score, pain scores at 0, 6, 12, 24, and 48 h postoperatively, time to first PONV episode and first rescue antiemetic, time to first rescue analgesic, total dosage and frequency of rescue analgesics and antiemetics within 48 h, patient satisfaction score at discharge, length of hospital stay, discharge condition, and the incidence and classification of adverse events. This study aims to evaluate the safety and feasibility of combining dexmedetomidine and esketamine to prevent PONV in patients undergoing laparoscopic surgery. The findings may offer evidence for an effective opioid-reducing anesthesia strategy that enhances analgesia and supports recovery, with potential value for broader clinical application. Chinese Clinical Trial Register, ChiCTR2300072455. Registered on June 14, 2023.


  • Radiation dose reduction and image quality in pediatric paranasal sinus CT: with automatic tube current modulation and iterative reconstruction technique

    by Xiao-Fang Chen, Yi-Chi Zhang, Ning Ding, Li Liu, Yi-Ding Ji, Chao Zhang, Jing Chi

    Our objective is to evaluate radiation dose and image quality in pediatric paranasal sinus computed tomography (CT) with automatic tube current modulation (ATCM) and sinogram-affirmed iterative reconstruction algorithm (SAFIRE). CT scans from 80 patients were divided into two groups: Group A [80 kVp, pitch 1.5, 40 mAs, the filtered back projection (FBP) algorithm] and Group B (70 kVp, pitch 3, ATCM with reference at 40 mAs, SAFIRE strengths 1–5). We have evaluated image quality and radiation dose. Group B demonstrated significantly lower volume computed tomography dose index, dose-length product, and effective dose than Group A (0.13 ± 0.03 vs. 1.57 ± 0.01 mGy, 2.27 ± 0.82 vs. 19.88 ± 2.01 mGy·cm, and 0.0081 ± 0.0017 vs. 0.079 ± 0.013 mSv, respectively; P < .001). Increasing SAFIRE strengths correlated with noise reduction and SNR enhancement. Group B’s noise and SNRsoft at SAFIRE strength 5 were comparable with Group A. Images reconstructed with SAFIRE strength 5 in Group B exhibit comparable image quality with FBP in Group A.


  • Open Access

    The diagnostic value of MSCT and MR imaging in intraductal papillary neoplasm of the bile duct

    by Chao Zhang, Chengcheng Wang, Shengnan Yin, Jing Chi

  • Open Access

    Massive subcutaneous emphysema and bilateral tension pneumothorax following laparoscopic inguinal hernia repair under general anesthesia: A case report

    by Suting Liu, Jing Chi, Hui Cao, Xinggen Zhou, Qingying Ma, Yang Yang, Jie Wang, Chao Zhang